To anyone from Generation X or older, it often feels like food allergies are far more common today than in their youth. While they remember them being rare or nonexistent in their school days, their own children will have classmates with allergies or they may have one themselves.
According to the Food Standards Agency, estimates suggest that about 5-8 percent of children and 1-2 percent of adults are affected by food allergies in the UK. The recent headlines about fatal allergic reactions, such as that of two Pret a Manger customers, heighten the impression that food allergies are more commonplace.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology company focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
